We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+25.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$288M
AUM Growth
+$45.4M
Cap. Flow
+$18.1M
Cap. Flow %
6.29%
Top 10 Hldgs %
61.77%
Holding
53
New
11
Increased
10
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.63M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.58M
3
HROW icon
Harrow
HROW
+$5.15M
4
KALV
KalVista Pharmaceuticals
KALV
+$4.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$4.3M

Top Sells

Rank Stock Value
1
CUTR
Cutera, Inc.
CUTR
+$6.74M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.25M
3
MRUS
Merus
MRUS
+$5.07M
4
KROS icon
Keros Therapeutics
KROS
+$3.89M
5
MRSN
Mersana Therapeutics
MRSN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
51
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-46,576
Closed -$412K
IMPL
52
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
– –
-255,250
Closed -$1.24M
INBX
53
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-292,700
Closed -$5.25M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2022 Portfolio in Review

As of Q4 2022, Opaleye Management held 53 positions worth $288M, up 19% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $18.1M of net new capital in Q4 2022, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was Biohaven: 540,000 shares worth $7.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $3.89M trimmed.

  • Opaleye Management's largest Q4 2022 buy was Biohaven: 540,000 shares worth $7.5M.
  • Opaleye Management added most to Harrow in Q4 2022, an estimated $5.15M increase.
  • Opaleye Management's biggest Q4 2022 reduction was Keros Therapeutics, cutting an estimated $3.89M.
  • Opaleye Management fully exited Cutera, Inc. in Q4 2022, selling an estimated $6.74M.
  • Opaleye Management's ten largest holdings make up 62% of its $288M portfolio in Q4 2022.
  • Opaleye Management opened 11 new positions and closed 13 in Q4 2022.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $288M.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.